Clinical Trial Update: A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating XELOXIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Colorectal Adenocarcinoma
• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• XELOXIRI

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Metastatic Cancer, Colorectal Cancer | Phase 1, Phase 2 | Status: UNKNOWN